• XXLP Targets NOX2/ROS/Mitochondria/NLRP3 Axis in Ulcerative

  2026-06-18

  Xu Chunfu’s Modified Xianglian Pill (XXLP) demonstrates significant therapeutic effects in a mouse model of ulcerative colitis by suppressing the NOX2/ROS/mitochondria/NLRP3 pathway and modulating gut microbiota composition. This study provides mechanistic insight into XXLP’s anti-inflammatory action, supporting new integrative strategies for colitis management.

• ICG001: Strategic Wnt/β-Catenin Pathway Inhibition in Transl

  2026-06-18

  This article explores how ICG001, a selective Wnt/β-catenin pathway inhibitor from APExBIO, empowers translational researchers to dissect and modulate CBP/β-catenin signaling across disease models. By blending recent mechanistic insights—including advances in stem cell osteogenesis, fibrosis, and cancer biology—with actionable protocol guidance and strategic considerations, we chart a path from bench discovery to clinical impact. Emphasis is placed on the unique selectivity of ICG001, evidence-backed workflows, and how this narrative expands beyond conventional product summaries to address unmet challenges in translational research.

• Quantifying Moloney MuLV: Novel qPCR Assay Distinguishes XRV

  2026-06-17

  Choi et al. present a sensitive real-time PCR method to quantify exogenous Moloney murine leukemia virus (M-MuLV) in mouse cells, addressing the challenge of distinguishing viral infection from endogenous retroviral background. This innovation enables rapid, accurate monitoring of M-MuLV replication and infectivity, streamlining virological research workflows.

• Myotubularin 2 Regulates Autophagy via SEC23A at ER Exit Sit

  2026-06-17

  This study reveals that Arabidopsis Myotubularin 2 (MTM2), a PtdIns3P phosphatase, localizes to ER exit sites and directly interacts with SEC23A to negatively regulate autophagy. The findings clarify a previously uncharacterized checkpoint linking autophagy initiation to COPII-mediated trafficking, with implications for understanding stress responses and membrane dynamics in plants.

• SU5416 (Semaxanib): Beyond VEGFR2 Inhibition in Vascular Bio

  2026-06-16

  Explore SU5416 (Semaxanib) as a VEGFR2 inhibitor and AHR agonist, uncovering its multifaceted applications in angiogenesis, immune modulation, and vascular cell metabolism. This article provides new insights for advanced cancer research and practical assay design.

• Wnt Agonist 1 (BML-284): Precision Control of Canonical Wnt

  2026-06-16

  Explore how Wnt agonist 1 (BML-284) enables precise, tunable activation of the canonical Wnt signaling pathway for advanced research in cellular differentiation and chemoresistance. This article uniquely dissects the mechanistic nuances, protocol optimization, and translational implications of Wnt pathway modulation, providing actionable insights for developmental and cancer biology.

• ATRA Overcomes Cisplatin-Induced PARP Inhibitor Resistance i

  2026-06-15

  This study uncovers how all-trans retinoic acid (ATRA) reverses cisplatin-induced resistance to PARP inhibition in epithelial ovarian cancer (EOC). By targeting metabolic and gene expression changes associated with resistance, ATRA enhances the efficacy of PARP inhibitors—offering a promising new maintenance strategy for platinum-experienced EOC patients.

• MMP7-Driven EMT via E-cadherin/β-Catenin Fuels Liver Fibrosi

  2026-06-15

  This study elucidates how matrix metalloproteinase 7 (MMP7) drives liver fibrosis in biliary atresia by inducing epithelial–mesenchymal transition (EMT) through E-cadherin cleavage and β-catenin signaling. The findings establish a mechanistic link between MMP7 activity and fibrogenic progression, offering new insights for targeted therapeutic strategies in pediatric liver disease.

• Meropenem Trihydrate in Modern Resistance Phenotyping Resear

  2026-06-14

  Explore how Meropenem trihydrate unlocks next-generation resistance phenotyping and metabolomics-based diagnostics. This article delves into its advanced scientific applications, bridging molecular insights with experimental workflows.

• ICG001: Wnt/β-Catenin Pathway Inhibitor in Fibrosis Models

  2026-06-13

  ICG001 enables precise dissection of Wnt/β-catenin signaling, offering selective pathway modulation for fibrosis and cancer research. Its CBP-specific inhibition profile supports high-fidelity mechanistic studies and robust translational workflows.

• Sisomicin: Protocols and Troubleshooting in Antibacterial Re

  2026-06-12

  Sisomicin stands out as a potent aminoglycoside antibiotic for rigorous in vitro and in vivo studies, offering distinct advantages for Gram-negative and Gram-positive infection models. This article translates current evidence and reference innovations into actionable protocols, troubleshooting, and comparative insights for researchers seeking robust, reproducible results.

• Triazole ALDH2 Activators: A New Frontier for Myocardial Isc

  2026-06-12

  This article reviews the design and evaluation of novel triazole-based small molecule activators of aldehyde dehydrogenase 2 (ALDH2) for myocardial ischemia therapy. These compounds, with markedly enhanced water solubility and unprecedented activation potency, address longstanding challenges in targeting ischemia-reperfusion injury, offering a basis for future translational research.

• ICG001: Precision Wnt/β-Catenin Inhibition for Advanced Dise

  2026-06-11

  Explore ICG001, a potent Wnt/β-catenin pathway inhibitor, and discover its unique selectivity for CBP/β-catenin interactions in cancer, fibrosis, and regenerative research. This article delivers new insights into targeted assay design and translational applications.

• Protease Inhibitor Cocktail: EDTA-Free Strategies for Protei

  2026-06-11

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO revolutionizes protein extraction in high-stakes applications such as OXPHOS-targeted cancer research and kinase assays. Its EDTA-free, broad-spectrum formulation offers unmatched compatibility and reproducibility, ensuring maximal protein integrity where it matters most.

• HSBP7 Loss Restores Function in Titin Cardiomyopathy Models

  2026-06-10

  Chopra et al. introduce CARDIO, a high-content imaging assay, to systematically profile morphological and functional alterations in human cardiomyocytes derived from induced pluripotent stem cells (iPS-CMs). Their study identifies HSPB7 loss as a novel modifier that reverses contractile dysfunction in titin-deficient dilated cardiomyopathy, offering new mechanistic insights for heart failure research.

16410 records 1/1094 page Next 12345 下5页 Last page